A Whole New Year For Pharma: Macro Pressures Mount Heading Into Q1 Reporting

 
• By Jessica Merrill

First quarter earnings preview: US drug pricing reform, an uncertain regulatory outlook and new focus on M&A are rising challenges that could put the industry's growth at risk.

Board game jenga tower of wood sticks
Regulatory and legislative uncertainty could mean more risk for pharma • Source: Alamy (Aleksandr Kichigin / Alamy Stock/Alamy Stock Photo)

More from Earnings

More from Business